Literature DB >> 1836782

The effect of indomethacin on basal and saline-stimulated plasma atrial natriuretic factor levels in normal man.

J A McKnight1, G Roberts, B Sheridan, A B Atkinson.   

Abstract

Surprisingly inappropriately high levels of plasma atrial natriuretic factor (ANF) in subjects with Bartter's syndrome are lowered by indomethacin therapy. Indomethacin in normal man causes sodium retention. One might therefore expect plasma ANF to increase in subjects taking indomethacin as a secondary phenomenon. On the other hand a decrease of plasma ANF in normal man similar to that reported in Bartter's subjects may explain the sodium retention caused by the drug in normals. We have studied plasma ANF before and during a two litre, four hour normal saline infusion in eight healthy male subjects both before and following five days of oral indomethacin. Plasma ANF basally was 4.2 +/- 0.9 pmol/l (mean +/- SEM) on no drug and 5.2 +/- 0.6 pmol/l on indomethacin (NS). It increased in response to saline in both studies (7.8 +/- 1.5 pmol/l after two litres of saline on control day; 10.6 +/- 1.5 pmol/l on the drug at the equivalent time, both p less than 0.05 vs basal value). Overall response to saline as assessed by the area under the curve above the basal value of hourly measurements, was not different in the two studies. Basal serum aldosterone and plasma renin activity were reduced by indomethacin. Urinary sodium excretion was not different between groups during the 12 hours before, four hours during and eight hours after the infusion. We have shown that indomethacin does not alter basal or saline stimulated plasma ANF in normal man, a finding in contrast to that reported in subjects with Bartter's syndrome. The sodium retention caused by indomethacin in normal man is not therefore due to a decrease of plasma ANF.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1836782     DOI: 10.1007/bf02957313

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  26 in total

1.  The pathophysiology of Bartter syndrome.

Authors:  N A Kurtzman; L F Gutierrez
Journal:  JAMA       Date:  1975-11-17       Impact factor: 56.272

2.  Bartter's syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin.

Authors:  R Verberckmoes; B van Damme B; J Clement; A Amery; P Michielsen
Journal:  Kidney Int       Date:  1976-03       Impact factor: 10.612

3.  Relationship between renal prostaglandin E and renal sodium handling during water immersion in normal man.

Authors:  M Epstein; M D Lifschitz; D S Hoffman; J H Stein
Journal:  Circ Res       Date:  1979-07       Impact factor: 17.367

Review 4.  Bartter's syndrome.

Authors:  J R Gill
Journal:  Annu Rev Med       Date:  1980       Impact factor: 13.739

5.  The effect of indomethacin on kidney function and plasma renin activity in man.

Authors:  A J Donker; L Arisz; J R Brentjens; G K van der Hem; H J Hollemans
Journal:  Nephron       Date:  1976       Impact factor: 2.847

6.  Release of natriuretic factor from rat heart-lung preparation by atrial distension.

Authors:  J R Dietz
Journal:  Am J Physiol       Date:  1984-12

7.  Bartter's syndrome--observations on the pathophysiology.

Authors:  L R Solomon; H Bobinski; P Astley; F S Goldby; N P Mallick
Journal:  Q J Med       Date:  1982

8.  The renal, cardiovascular and hormonal actions of human atrial natriuretic peptide in man; effects of indomethacin.

Authors:  I Miyamori; M Ikeda; T Matsubara; S Okamoto; H Koshida; S Yasuhara; T Morise; R Takeda
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

9.  Acute increase in right atrial pressure by intracardiac stimulation releases atrial natriuretic peptide.

Authors:  M C Haufe; J Weil; K Nafzger; R Gerzer; F Bidlingmaier; K Theisen
Journal:  Eur Heart J       Date:  1987-03       Impact factor: 29.983

10.  Plasma levels of atrial natriuretic peptide in primary aldosteronism and essential hypertension.

Authors:  T Yamaji; M Ishibashi; H Sekihara; F Takaku; H Nakaoka; J Fujii
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.